ClinicalTrials.gg
RecruitingNCT07404826PEPRUpdated Jul 24, 2026

PEP Buddy in Pulmonary Rehabilitation

An interventional study of PEP Buddy and PEP Buddy Sham in COPD, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 40 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Pulmonary Disease, Chronic Obstructive by VA Office of Research and Development — 10 open to participants now, 11 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · VA Office of Research and Development.

Planned enrollment
17th of 33
120 · median 120
Started
2026
with 2 others
No phase
30 of 36
9 open now
Primary completion
2030-07
later than 10 of 10 live
Registered
34th of 36
by date

Among the 36 studies in Pulmonary Disease, Chronic Obstructive by VA Office of Research and Development, this one is the 17th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 30 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 34th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

10 of the 36 studies in Pulmonary Disease, Chronic Obstructive by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pulmonary Disease, Chronic Obstructive by VA Office of Research and Development, or all of them as a file.
02

Study summary

In this study, the investigators will test Veterans with COPD in Pulmonary Rehabilitation. Between two groups, the investigators will give one group a device that assists with breathing and symptoms and the other receives a 'sham' device which does not provide these benefits. The investigators will test to see if the symptoms and exercise capacity of the group who receives this device improves faster in Pulmonary Rehabilitation and has longer lasting benefits after the end of Pulmonary Rehabilitation.

Read the detailed description

In this randomized, double-blinded, sham-controlled clinical trial, the investigators will test the effectiveness of the use of a positive expiratory device (PEP Buddy) vs. sham in participants with COPD in Pulmonary Rehabilitation and after discharge from Pulmonary Rehabilitation for up to one year. The investigators will compare changes in quality of life metrics and measurements of functional capacity between the intervention and sham groups over the course of the study.

03

Conditions studied

  • COPD

Keywords

  • Pulmonary Rehabilitation
04

Who can participate

Ages eligible
40 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veteran
  • Referral to Pulmonary Rehabilitation for
  • \<80% predicted
  • Participants must be able to exercise on 4L/m nasal cannula O2

Exclusion criteria

Exclusion Criteria:

  • Those deemed by the study personnel to have a lung disease other than impacting their daily dyspnea
  • Those that are unable to perform study procedures or are unwilling or unable to use PEP Buddy
  • Those that have a component of lung disease driven by aspiration or neurological conditions affecting the face or oropharynx
  • Those with a of \<1 year
  • Those with a known surgical intervention that will require a prolonged recovery in the year after enrollment
  • Those with a beyond Stage I or non-melanoma skin cancer
  • Those shown shown to have memory loss of MOCA testing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    PEP Buddy

    This arm will be provided with a portable device that provides 5-7 cm H2O of expiratory pressure, to be used when subjectively breathless

    Device: PEP Buddy

  • Sham comparator
    Sham

    This arm will be provided with a portable device that appears the same as PEP Buddy but provides 1-3 cm H2O of expiratory pressure, to be used when subjectively breathless

    Device: PEP Buddy Sham

Interventions

  • DevicePEP Buddy

    This is a small, portable device worn about the neck with a lanyard, that can be used to control symptoms of breathlessness associated with chronic lung disease.

  • DevicePEP Buddy Sham

    A Device that appears the same as PEP Buddy but only provides the expiratory pressure of the standard-of-care pursed lip breathing

    Also known as: Sham

06

What researchers measure

Primary outcomes

  1. San Diego Shortness of breath Questionnaire

    This is a standardized survey used to quantify the impact of daily respiratory symptoms on quality of life. This will be collected on enrollment and the investigators will compare the change between groups at Weeks 3, 6, 9, and 12 and at six-and twelve-months after enrollment.

    Time frame: 12 Months

  2. Daily steps measured by wrist-wron accelerometer

    Using accelerometry, the investigators will show the changes in daily step counts between groups over the one year of time in the study.

    Time frame: 12 Months

Secondary outcomes

  1. One-Minute Sit to Stand test

    The investigators will perform this test at enrollment and at weeks 3, 6, 9, and 12 as well as six-and twelve-months after enrollment and compare between groups. This test calculates the number of times a participant can sit and rise from a chair over the course of a minute.

    Time frame: 12 Months

  2. Six Minute Walk Test

    A standard test of exercise capacity in those with chronic lung disease. The investigators will assess changes in the six-minute walk test difference from enrollment at Weeks 3, 6, 9, and 12 in the study and at six-and twelve-months after the conclusion of the study.

    Time frame: 12 months

  3. St. George Respiratory Questionaire

    The investigators will compare the values between groups from enrollment at Weeks 3, 6, 9, and 12 and at six-and twelve-months after enrollment. This is a standard survey form in which participants report the severity and daily impact of respiratory symptoms and how they may inhibit daily activity.

    Time frame: 12 Months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The investigators will share data with VA researchers that will be de-identified via Safe Harbor approach. However, if a non-VA researcher requests aggregate data, the investigators will work with local research office, facility privacy officer, and information security officer to identify an applicable agreement for data sharing. No VA data will include any PHI to any non-VA researchers requesting VA data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data will not be shared until the close of the study (March 2025). The investigators will then share data for six years after close of study.

Access criteria: The investigators ask that any requesting entity contact the Primary Investigator by e-mail to begin a request for data via VA processes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2030, 48 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 48 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 12, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Jul 29, 2030
CompletionEst.
Jul 29, 2030
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404826
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Jul 16, 2026
Primary completion
Jul 29, 2030 (estimated)
Completion
Jul 29, 2030 (estimated)
Last update
Jul 24, 2026

Study contacts

Robert M Burkes, MD MS
Contact
robert.burkes@va.gov
(724) 730-3862
Robert Matthew Burkes, MD MS
principal investigator · Cincinnati VA Medical Center, Cincinnati, OH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion